Cargando…

PB2051: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC/EFFICACY MODELING OF SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) AND REFERENCE ECULIZUMAB

Detalles Bibliográficos
Autores principales:	Lee, Hyuna, Park, Jihye, Jang, Hyerin, Kim, Jungryul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429643/ http://dx.doi.org/10.1097/01.HS9.0000975004.91980.ef

Ejemplares similares

A phase III, randomised, double‐blind, multi‐national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria
por: Jang, Jun Ho, et al.
Publicado: (2022)

A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects
por: Lee, Hyun A, et al.
Publicado: (2022)

P829: A PHASE III RANDOMIZED CLINICAL TRIAL COMPARING SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) WITH REFERENCE ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Jang, J. H., et al.
Publicado: (2022)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
por: Monteleone, Jonathan P. R., et al.
Publicado: (2021)

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder
por: Singh, Pratap, et al.
Publicado: (2021)

PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Kulasekararaj, Austin, et al.
Publicado: (2023)

P815: PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY OF ABP 959 AND ECULIZUMAB REFERENCE PRODUCT: UNBOUND ECULIZUMAB AND CH50 FROM THE RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE STUDY IN HEALTHY VOLUNTEERS
por: Hanes, V., et al.
Publicado: (2022)

In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period
por: Tak, Minji, et al.
Publicado: (2023)

PB1934: REAL-WORLD OUTCOMES OF ECULIZUMAB TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINUREA: A SYSTEMATIC LITERATURE REVIEW AND EVIDENCE SYNTHESIS
por: Nishimura, J.-I., et al.
Publicado: (2022)

PB2051: PRIMARY MYELOFIBROSIS IN YOUNG PATIENTS ≤50 YEARS: CLINICOPATHOLOGICAL CHARACTERISTICS, GENETIC LANDSCAPE AND DISEASE OUTCOME. A SINGLE CENTER EXPERIENCE
por: Elkourashy, S., et al.
Publicado: (2022)

Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab
por: Kulagin, Alexander D., et al.
Publicado: (2021)

Eculizumab Dosing in Infants
por: Kobrzynski, M., et al.
Publicado: (2018)

Eculizumab in Early-Stage Pregnancy
por: Morales, Enrique, et al.
Publicado: (2020)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product
por: Hutterer, Katariina M., et al.
Publicado: (2021)

Eculizumab in recalcitrant antiphospholipid antibody syndrome
por: Zapantis, Ekaterini, et al.
Publicado: (2014)

Treating C3 glomerulopathy with eculizumab
por: Welte, Thomas, et al.
Publicado: (2018)

Eculizumab in chemotherapy-induced thrombotic microangiopathy
por: Schulte-Kemna, Lena, et al.
Publicado: (2020)

Eculizumab: COVID-19: case report
Publicado: (2021)

Eculizumab for refractory thrombosis in antiphospholipid syndrome
por: Hussain, Habiba, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies
por: Peffault de Latour, Régis, et al.
Publicado: (2020)

Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria
por: Eliesen, Gaby A.M., et al.
Publicado: (2020)

The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
por: Kelly, Richard, et al.
Publicado: (2009)

The effects of Eculizumab on the pathology of malignant atrophic papulosis
por: Magro, Cynthia M, et al.
Publicado: (2013)

Treatment of atypical uraemic syndrome in the era of eculizumab
por: Fremeaux-Bacchi, Veronique
Publicado: (2012)

Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013)

Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)

Timing of eculizumab therapy for C3 glomerulonephritis
por: Rodriguez-Osorio, Laura, et al.
Publicado: (2015)

Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

The use of eculizumab in gemcitabine induced thrombotic microangiopathy
por: Krishnappa, Vinod, et al.
Publicado: (2018)

Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017)

The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
por: Gabr, Jihad Ben, et al.
Publicado: (2020)

Eculizumab/tocilizumab: Various toxicities: case report
Publicado: (2020)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Eculizumab's Unintentional Mayhem: A Systematic Review
por: Dhanoa, Ravneet K, et al.
Publicado: (2022)

Eculizumab in the treatment of neuromyelitis optica spectrum disorder
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_62ddt00998hau6q91htfk273ub